glp 1 drugs and thyroid cancer Does Using GLP-1 Drugs, Like Zepbound or Wegovy, Increase Your Risk of Cancer? Frontiers | Drug repositioning in

doi: 10.1185/03007990802418851 111 EganAGBlindEDunderKde GraeffPAHummerBTBourcierTet al

In expanded populations, comparing semaglutide versus sitagliptin for the composite outcome of myocardial infarction or stroke yielded a hazard ratio of 0.82 (95% confidence interval (CI) 0.74 to 0.91), and comparing tirzepatide versus dulaglutide for the composite outcome including mortality yielded a hazard ratio of 0.87 (95% CI 0.75 to 1.01)

Health Insurers: There is growing pressure on health insurers to consider the coverage of GLP-1RA drugs for weight-loss purposes, particularly in the wake of trial results that show the broader health benefits

Pharmacologically reversible zonation-dependent endothelial cell transcriptomic changes with neurodegenerative disease associations in the aged brain

Improvements in post-challenge lipid response following tirzepatide treatment in patients with type 2 diabetes

After administration of Exendin-4, A oligomers-induced impaired axonal transport was prevented, and levels of soluble A and amyloid plaque load were decreased in APP/PS1 mice (224, 227)